Sputum-plasma ratio of soluble receptor for advanced glycation end-products in patients with chronic obstructive pulmonary disease

详细信息    查看全文

• 作者：Essam Gouda Hassanein^a ; ^{saragouda@hotmail.com" class="auth_mail" title="E-mail the corresponding author} ; Anwar Ahmad ElGanady^a ; ^{a.ganady@hotmail.com" class="auth_mail" title="E-mail the corresponding author} ; Ayman Ibrahim Baess^a ; ^{ayman.baeis@yahoo.com" class="auth_mail" title="E-mail the corresponding author} ; Yasmine Amr Issa^b ; ^{yasmineamr2004@yahoo.com" class="auth_mail" title="E-mail the corresponding author} ; Essam Mohamed ElAkhtel^c ; ^{emk_f@yahoo.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：COPD ; Receptor for advanced glycation end products ; Soluble form of RAGE ; Inflammatory marker
• 刊名：Egyptian Journal of Chest Diseases and Tuberculosis
• 出版年：2016
• 出版时间：July 2016
• 年：2016
• 卷：65
• 期：3
• 页码：573-578
• 全文大小：694 K

文摘

Chronic obstructive pulmonary disease (COPD) is associated with systemic inflammatory consequences. Receptor for advanced glycation end products (RAGE) acts as an important progression factor amplifying the immune and inflammatory responses in several pathophysiological conditions. The soluble form of RAGE (sRAGE) acts as a decoy for the receptor ligands and is thus thought to protect against excessive inflammation. Conflicting reports exist about sRAGE value in stable and exacerbating COPD.

Objective

To assess the sputum to plasma ratio of sRAGE in stable COPD patients.

Subjects and methods

The study included 44 adult patients of both sexes who were presented to Alexandria Main University Hospital between March and July 2015. Patients were categorized into three groups; 15 stable COPD patients (Group I), 15 smokers without COPD (Group II), and 14 healthy non-smokers (Group III). Measurement of sRAGE level in induced sputum and plasma was performed using ELISA technique.

Results

The study included 38 male patients and 6 female patients, whose median ages were 50, 42 and 35.5 years in Groups I, II, and III respectively (p < 0.001). Median FEV₁% predicted were 35, 96, and 105% in Groups I, II, and III respectively (p < 0.001). No statistical significant difference was found among all groups regarding sRAGE level in induced sputum, plasma or sputum/plasma ratio (p = 0.092, 0.372, 0.154, respectively). Although levels of sRAGE is apparently higher in induced sputum rather than in plasma, it lacked significance (r = 0.27, p = 0.08). Furthermore, no significant correlation was found between either plasma or sputum sRAGE level and predicted FEV₁% (r = −0.11, p = 0.48 and r = −0.12, p = 0.28, respectively).

Conclusions

sRAGE level either in induced sputum, plasma or sputum plasma ratio is not significantly different between stable COPD patients, smokers and healthy controls. Thus, sRAGE cannot be considered as a marker of either diagnosis or severity of COPD.